Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

PHASE4CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Pulmonary EmbolismThromboembolismVascular DiseasesThrombosis
Interventions
DRUG

Nadroparin

LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.

DRUG

Unfractionated heparin(UFH)

UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.

Trial Locations (39)

100034

Peking University First Hospital, Beijing

100036

Beijing General Hospital of the Air-force PLA, Beijing

100037

Beijing Naval General Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100083

Beijing No 6 Hospital, Beijing

Peking University Third Hospital, Beijing

100730

Beijing Hospital, Beijing

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

110001

The First Hospital of China Medical University, Shenyang

110016

The General Hospital of Shenyang Military Command, Shenyang

110024

The Affiliated Hospital of Shenyang Medical University, Shenyang

114002

Liaoning Angang Tiedong Hospital, Anshan

200025

Shanghai Ruijin Hospital, Shanghai

200433

Shanghai Changhai Hospital, Shanghai

Shanghai Pulmonary Hospital(8), Shanghai

250012

Qilu Hospital Affiliated to Shandong University, Jinan

264001

Shandong Yantaishan Hospital, Yantai

266003

The Affiliated Hospital of Medical College Qingdao, Qingdao

272029

The Affiliated Hospital of Medical College Jining, Jining

300051

Tianjin Thoracic Hospital, Tianjin

300052

Tianjin Medical University General Hospital, Tianjin

310016

Sir Run Run Shaw Hospital, Affiliated with Zhejiang University, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Medical College, Wenzhou

430022

Wuhan Union Hospital, Wuhan

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510120

The First Affiliated Hospital Sun Yat-Sen University, Guangzhou

Guangzhou Institute of Respiratory Disease,Guangzhou Medical University, Guangzhou

510630

The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou

518020

Shenzhen People's Hospital, Shenzhen

530027

The First Affiliated Hospital of Guangxi Medical University, Nanning

750004

The Affiliated Hospital of Ningxia Medical University, Yinchuan

830001

Xinjiang People's Hospital, Ürümqi

050000

The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang

063000

Tangshan Worker's Hospital, Hebei Medical University, Tangshan

The Affiliated Hospital of Hubei Coal University, Tangshan

037006

Shanxi Datong 5th Hospital, Datong

030001

The First Affiliated Hospital of Shanxi Medical University, Taiyuan

The Second Affiliated Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors
lead

Beijing Chao Yang Hospital

OTHER

NCT00796692 - Nadroparin for the Initial Treatment of Pulmonary Thromboembolism | Biotech Hunter | Biotech Hunter